“The challenge for investors who are looking to cash in on the hype surrounding a Covid-19 vaccine is placing their bets on the right horse,” acknowledges the author of today’s article. He proceeds to highlight one vaccine developer whose proprietary “FastPharming” technology – which could help it rapidly scale up production of its Covid-19 vaccine candidate if it’s approved – helps it stand out among the various biotech firms participating in the Covid-19 vaccine race. For more on this firm – whose stock has gained an astounding 524% since last year – CLICK HERE.